Big Money Elevating United Therapeutics

The biotechnology company offers four medicines to treat PAH, which is a form of elevated blood pressure in the lungs, as well as treatments for other diseases. It also conducts cutting-edge medical research, which could bring longer-term growth opportunities. Additionally, UTHR recently began a partnership to use AI to diagnose unrecognized PAH cases.

The company’s financial performance is capturing investor attention too. In its March report, the company showed 33.7% revenue growth and a net margin of 45.2%. UTHR also has a low debt-to-equity ratio of just 0.11, reflecting a small use of debt financing and conservative cash management.

It’s no wonder UTHR shares are up 44% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

United Therapeutics Shares in Demand

Institutional volumes reveal plenty. Recently, UTHR has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in UTHR shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with United Therapeutics.

United Therapeutics Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, UTHR has had strong sales and earnings growth:

• 3-year sales growth rate (+16.2%)
• 3-year EPS growth rate (+24.5%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +10%.

Now it makes sense why the stock has been powering to new heights. UTHR has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

United Therapeutics has been a top-rated stock at MAPsignals for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last 20 years. The blue bars below show when UTHR was a top pick…soaring with time:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

United Therapeutics Price Prediction

The UTHR rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in UTHR at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.